Mekinist (Trametinib) – NSCLC | DengYue Medicine

Mekinist Application Scope

Mekinist is an oral MEK1/MEK2 inhibitor used in treating BRAF V600-mutant cancers.

Characteristics

• Ingredients: Trametinib

• Properties:

  • Oral kinase inhibitor against MEK1/2, interrupting MAPK signaling

  • Available as film-coated tablets (0.5 mg yellow oval, 2 mg pink round)

• Packaging Specification: Tablets supplied in bottles of 7 or 30 with screw-cap closures

• Storage: Store in original container at controlled room temperature, protect from moisture

• Expiry Date: ​Refer to bottle label; typically two years from manufacture

• Executive Standard: Conforms to FDA, EMA, and Health Canada prescribing information

• Approval Number: US NDA 204114; Health Canada authorization under the same references

• Date of Revision: US labeling updated January–March 2025

• Manufacturer: Novartis Europharm Limited (Ireland); tablets produced in Slovenia (Lek)

Guidelines for the Use of Mekinist

• Dosage and Administration:

  • Adults: 2 mg orally once daily, at least 1 hour before or 2 hours after food

  • Pediatric: weight-based dosing (e.g., 1 mg for 26–37 kg; 2 mg for ≥51 kg)

  • Combination:

    • used with dabrafenib 150 mg twice daily for BRAF-mutant melanoma

    • NSCLC, thyroid cancer, glioma

  • Dose reduction steps: 1.5 mg → 1 mg → hold/discontinue if not tolerated

• Adverse Reactions:

  • Common:

    • rash, diarrhea, fatigue, peripheral edema, nausea, acneiform dermatitis

  • With dabrafenib:

    • fever, chills, headache, arthralgia, hemorrhage, cardiomyopathy, ocular issues

• Contraindications:

  • Hypersensitivity to trametinib or excipients

  • No other absolute contraindications are listed

• Precautions:

  • Monitor for new primary malignancies, bleeding

  • DVT/PE, cardiomyopathy, retinal vein occlusion, interstitial lung disease

Mekinist Interactions

• Drug Interactions:

  • Avoid strong CYP3A4 inducers or inhibitors

  • Space dosing around such medications

Note:

• If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
• It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.